A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus
Currently, there are no treatments or vaccines against Epstein-Barr virus (EBV) infection. Here, Zhu et al. isolate gH/gL-specific antibodies from infected donors and identify 1D8, that substantially reduces infection levels in both, B- and epithelial cells, and reduces tumor burdens in EBV-challang...
Guardado en:
Autores principales: | Qian-Ying Zhu, Sisi Shan, Jinfang Yu, Si-Ying Peng, Cong Sun, Yanan Zuo, Lan-Yi Zhong, Shu-Mei Yan, Xiao Zhang, Ziqing Yang, Yong-Jian Peng, Xuanling Shi, Su-Mei Cao, Xinquan Wang, Mu-Sheng Zeng, Linqi Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2239cf6967614df582f09b6994a16020 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
por: Qian-Ying Zhu, et al.
Publicado: (2020) -
Atomic structure of the Epstein-Barr virus portal
por: Cristina Machón, et al.
Publicado: (2019) -
Competitive Endogenous RNA Landscape in Epstein-Barr Virus Associated Nasopharyngeal Carcinoma
por: Xiandong Lin, et al.
Publicado: (2021) -
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
por: Jiwan Ge, et al.
Publicado: (2021) -
Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinoma
por: Dan Tao, et al.
Publicado: (2020)